Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on BioVersys AG. The associated price target remains the same with CHF40.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ram Selvaraju has given his Buy rating due to a combination of factors related to BioVersys’ strengthened strategic and clinical position. He views the exclusive collaboration with Hackensack Meridian Health as a value-enhancing move that meaningfully expands the company’s ansamycin chemistry portfolio, builds on prior work with Shionogi, and broadens the set of potent, orally available anti-NTM candidates as well as other antimicrobial prospects.
He also places significant weight on the late-stage status and design of the pivotal Phase 3 BV100 program in difficult-to-treat CRABC HABP/VABP, which includes both randomized and open-label components and targets meaningful endpoints such as 28-day mortality and clinical cure. In his assessment, the expected 2027 data timeline, planned 2028 regulatory submissions in major markets, and the company’s cash position that should fund operations beyond the BV100 readout collectively justify a positive risk-reward profile that supports a Buy rating and a CHF40 price target.
In another report released on March 31, Stifel Nicolaus also reiterated a Buy rating on the stock with a CHF70.00 price target.